446 related articles for article (PubMed ID: 35609888)
1. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.
Gazit S; Saciuk Y; Perez G; Peretz A; Pitzer VE; Patalon T
BMJ; 2022 May; 377():e071113. PubMed ID: 35609888
[TBL] [Abstract][Full Text] [Related]
2. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.
Patalon T; Gazit S; Pitzer VE; Prunas O; Warren JL; Weinberger DM
JAMA Intern Med; 2022 Feb; 182(2):179-184. PubMed ID: 34846533
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
Grewal R; Kitchen SA; Nguyen L; Buchan SA; Wilson SE; Costa AP; Kwong JC
BMJ; 2022 Jul; 378():e071502. PubMed ID: 35793826
[TBL] [Abstract][Full Text] [Related]
4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
5. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Amir O; Freedman L; Alroy-Preis S; Ash N; Huppert A; Milo R
N Engl J Med; 2022 May; 386(18):1712-1720. PubMed ID: 35381126
[TBL] [Abstract][Full Text] [Related]
6. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel.
Cohen MJ; Oster Y; Moses AE; Spitzer A; Benenson S;
JAMA Netw Open; 2022 Aug; 5(8):e2224657. PubMed ID: 35917125
[TBL] [Abstract][Full Text] [Related]
7. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Magen O; Waxman JG; Makov-Assif M; Vered R; Dicker D; Hernán MA; Lipsitch M; Reis BY; Balicer RD; Dagan N
N Engl J Med; 2022 Apr; 386(17):1603-1614. PubMed ID: 35417631
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
10. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
11. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
12. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
Muhsen K; Maimon N; Mizrahi AY; Boltyansky B; Bodenheimer O; Diamant ZH; Gaon L; Cohen D; Dagan R
JAMA Intern Med; 2022 Aug; 182(8):859-867. PubMed ID: 35737368
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
16. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
[TBL] [Abstract][Full Text] [Related]
17. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
18. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD
Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
